Identification of Antibodies against Human Papillomavirus Type 16 E6 and E7 Protein in Sera of Patients with Cervical Neoplasias

宫颈肿瘤患者血清中人乳头瘤病毒16型E6和E7蛋白抗体的鉴定

• 批准号: 04671001
• 负责人: INOUE Masaki
• 金额: $ 1.28万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1992
• 资助国家: 日本
• 起止时间: 1992 至 1993
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-04671001/
• 关键词: Human papillomavirus; Antibody; Early gene product; Fusion protein; Tumor marker; 融合蛋白; HPV抗体価測定系; HPV DNA 16型; 抗体; ELISA; 抗体測定系; 腫瘍マーカー; 子宮頚癌

We have developed a sensitive and specific ELISA method using the s10-fusion proteins of human papillomavirus (HPV) 16 E6 and E7, expressed in E.coli. Sera from 97 women(30 patients with invasive cervical cancers 26 patients with cervical intraepithelial neoplasea III (CIN III) and 38 healthy women) were tested for the presence of antibodies to E6 and E7 proteins. Eight (27%) of the 30 cervical cancer sera, five (19%) of the 26 CIN sera and none of the38 normal sera were reactive with E6 proteins(cut-off point : absorbance (A)=0.59, x+3SD). Ten (33%) of the 30 cervical cancer sera, two (8%) of the 26 CIN III sera and none of the 38 normal sera were reactive with E7 proteins (cut-off point : A=0.40, x+3SD). The mean absorbance for anti-E7 antibody in positive cases was higher in cancer patients than in CIN III patients, while that for E6 did not differ between these two groups. Interstingly, six (50%) of 12 cancer sera which reacted with either E6 or E7 proteins were reactive for both proteins, whereas none of the sera from the CIN III patients reacted with both proteins. The high prevalence rates and high absorbance values for HPV 16 E6 and E7 antibodies in association with malignant transformation suggest that detection of these antibodies may be a useful diagnostic aid for cervical cancer-associated HPV 16.

我们已经使用人乳头瘤病毒（HPV）16 E6和E7的S10融合蛋白开发了一种敏感的ELISA方法，该蛋白在E.Coli中表达。测试了97名女性（30例侵入性宫颈癌患者26例颈椎内肿瘤III（CIN III）和38位健康女性）的血清，以抗E6和E7蛋白的抗体存在。在30个宫颈癌血清中，有8个（27％），26个CIN血清中的5个（19％），而38个正常血清都没有E6蛋白反应性（截止点：吸光度：a）= 0.59，x+3sd）。在30个宫颈癌血清中有10个（33％），26个CIN III血清中的2个（8％），而38种正常血清都没有E7蛋白反应性（截止点：A = 0.40，X+3SD）。癌症患者中抗E7抗体的平均吸光度高于CIN III患者，而E6的平均抗体在这两组之间没有差异。偶然地，与E6或E7蛋白反应的12种癌症中有6种（50％）对两种蛋白质反应性，而CIN III患者的血清均未与两种蛋白质反应。与恶性转化有关的HPV 16 E6和E7抗体的高患病率和高吸光度值表明这些抗体的检测可能是宫颈癌相关的HPV 16的有用诊断辅助。

项目成果

Sasagawa T, Inoue M, Tanigawa O, Yutsudo M, Hakura A: "Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical Neoplasias" Jpn. J.Cancer Research. 83. 705-713 (1992)

Sasakawa T、Inoue M、Tanikawa O、Yutsudo M、Hakura A：“宫颈肿瘤患者血清中人乳头瘤病毒 16 型 E6 和 E7 蛋白抗体的鉴定”Jpn。

Fujita M,Inoue M,et al.: "Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection." Cancer Research. 52. 5323-5328 (1992)

Fujita M、Inoue M 等人：“有或没有人乳头瘤病毒感染的人原发性宫颈癌中 p53 基因的改变。”

Sasagawa T,Inoue M,Tanizawa O,Yutsudo M,Hakura A: "Identification of antibody against human papillomevirus type 16 E^6 and E_7 proteins in sera of patients with cervical neoplagias" Jpn J.Cancer Research. 83. 705-713 (1992)

Sasakawa T、Inoue M、Tanizawa O、Yutsudo M、Hakura A：“宫颈肿瘤患者血清中针对人乳头状病毒 16 型 E^6 和 E_7 蛋白的抗体的鉴定”Jpn J.Cancer Research。

Sasagawa T,Inoue M,Tanizawa O,Yutsudo M,Hakura A: "Identification of antibodies against human papillomavirus type16 E_6 and E_7 proteins in sera of patients with clinical Neoplasias" JPN J Cancer Research. 83. 705-713 (1992)

Sasakawa T、Inoue M、Tanizawa O、Yutsudo M、Hakura A：“临床肿瘤患者血清中针对人乳头瘤病毒 16 型 E_6 和 E_7 蛋白的抗体的鉴定”JPN J Cancer Research。

Inoue M,Nakazawa A Fujita M,Tanizawa O: "Human papillomavirus(HPV)type 16 in semen of partners of women with HPV infection" The Lancet. 339. 1114-1115 (1992)

Inoue M、Nakazawa A Fujita M、Tanizawa O：“HPV 感染女性伴侣精液中的人乳头瘤病毒 (HPV) 16 型”《柳叶刀》。